Below The Knee | State of the Market

The WoundCareFund closed the week up +0.77%, trailing a strong tech-led rally but finishing positive. The NASDAQ Composite surged +3.32%, the S&P 500 gained +1.42%, while the Dow Jones Industrial Average slipped -0.47%. Inside wound care and medtech, this was another stock picker's market week.

Upside leadership: Integra LifeSciences (+28.65%) and Tela Bio (+26.44%) led the week. Integra's surge followed its Q1 beat — a 33% EPS surprise and revenue above guidance triggered a decisive re-rating. When expectations have been compressed and execution improves, Integra can move quickly. Tela's move reflects building momentum around the OviTex platform and soft tissue reconstruction story — moves of this size typically signal improving growth confidence, expanding surgeon adoption, and investors leaning back into higher-beta medtech.

Downside pressure: InfuSystem Holdings (-11.45%) and Biostem Technologies (-8.87%) gave back ground. InfuSystem's pullback likely reflects profit-taking after prior strength and continued sensitivity around utilization trends in infusion services. Biostem remains in the high-volatility pattern that defines the regenerative medicine and placental-derived biologics category — investor sentiment shifts quickly around reimbursement outlook, scaling expectations, and liquidity.

April Was the Month the Market Stopped Guessing.

The first full quarter of the post-CMS change era is on the record. Q1 2026 earnings didn't just confirm the thesis, they quantified it. The companies that were built right are separating from the ones that weren't, and the gap is not a rounding error.

MiMedx reported wound care revenue down 60% year over year. Organogenesis missed even its own reduced guidance — Q1 revenue came in at $36.3M, -58% YoY, and full-year guidance was cut to $270–$310M from $350–$420M. Coloplast zeroed out its Kerecis growth outlook. Integra LifeSciences beat on every line and surged 24% in a single session. Solventum raised its full-year earnings outlook driven by wound care demand. Smith+Nephew absorbed the skin substitute reset and grew overall. Aroa Biosurgery beat guidance on 52% Myriad growth. The DOJ seized $2 million from a Pasadena clinic alleged to have billed $46.6 million in fraudulent Medicare claims.

Seven stories. One through line. The reimbursement filter CMS designed is working exactly as designed — and Q1 2026 gave the market its first full, quantified look at who built for it and who didn't.

SAWC Spring in Charlotte set the conference backdrop for this cycle. The floor confirmed what the earnings reports said: the companies worth paying attention to had data, channel diversification, and a clear answer to the documentation standard the market now requires. The ones that didn't were having a different kind of conversation.

This edition synthesizes the full Q1 2026 earnings picture, the EWMA-DEWU conference signal from Bremen, April's market developments by category, and three forward reads heading into the balance of 2026.

✓ = reported · upcoming = report date noted

MiMedx (NASDAQ: MDXG) — Reported April 29 ✓ Net sales $59M, -33% YoY. Wound care -60%. Surgical +13%. Full-year guidance $260–$290M. Return to profitability targeted Q3. Management cut $40M in annualized operating costs, eliminated the COO role, and reduced executive salaries. CEO Joe Capper's characterization of the recovery as "very slow — along with the broader market" is the most consequential phrase in any Q1 wound care earnings call. It is not a company-specific admission. It is a sector-level signal delivered in an 8-K.

Coloplast — Guidance Cut Announced April 23 ✓ Full H1 results expected in May. Kerecis at 0% organic growth; full-year guidance cut to 5–6%. If even Kerecis — one of the category's strongest evidence stories with a differentiated 510(k) position — is seeing disruption of this magnitude, the floor for undifferentiated amniotic products is structurally lower than most guidance implied going into the year.

Aroa Biosurgery (ASX: ARX) — Preliminary FY26 Results Released ✓ Revenue NZ$104M, above guidance. Myriad +52%. Full FY26 results due by May 31. Aroa's OviTex platform operates primarily in the surgical reconstruction channel — less exposed to the outpatient skin substitute reset than pure wound care players. The channel distinction is the single most predictive variable in Q1 2026 wound care results.

Smith+Nephew (LSE: SN / NYSE: SNN) — Reported May 6 ✓ Q1 total revenue $1.50B, +3.1% underlying, +6.6% reported. Advanced Wound Management $411M, +2.2% underlying. Within AWM: Advanced Wound Care (foam, dressings) +4.9% underlying led by ALLEVYN LIFE; Advanced Wound Bioactives -1.7% underlying driven by the skin substitute reimbursement reset; Advanced Wound Devices +1.9%. SANTYL enzymatic debrider delivered double-digit growth. Management characterized the skin substitute impact as "in line with expectations" and maintained full-year guidance of ~6% underlying revenue growth and a new $500M share buyback. The divergence within Smith+Nephew's own wound portfolio is a clean illustration of the broader market sort: foam and devices are growing; bioactives exposed to the CMS reset are not.

Integra LifeSciences (NASDAQ: IART) — Reported May 5 ✓ Q1 revenue $391.9M, +2.4% reported, +1.3% organic. Adjusted EPS $0.54 vs $0.41 consensus — a 33% beat. Stock surged +24.1% on the session. Tissue Reconstruction (which includes Integra Skin) grew 6.7% organically with double-digit growth in Integra Skin and mid-double-digit growth in DuraSorb. Full-year revenue guidance reaffirmed at $1.662–$1.702B; adjusted EPS guidance raised to $2.40–$2.50. Integra is executing its post-recall transformation with enough operational momentum that the market reacted decisively. For the BTK coverage universe, Integra Skin's performance in a reset environment is a direct signal about where evidence-differentiated regenerative tissue products are headed.

Solventum (NYSE: SOLV) — Reported May 5 ✓ Q1 revenue $2.01B, +2.1% organic, beating consensus of $1.97B. Adjusted EPS $1.48 vs $1.35 consensus. Advanced Wound Care delivered 2.1% organic growth within MedSurg, with Acera contributing $28M in reported sales. MedSurg segment overall grew 6.6% to $1.23B — more than half of total company revenue. Management raised full-year profit guidance to the higher end of the prior $6.40–$6.60 per share range, citing wound care and sterilization demand as primary drivers. Solventum's wound care performance — stable growth, Acera integration on track — is the large-cap counterpoint to the CAMP-driven disruption: companies with diversified, durable wound care portfolios that were not dependent on skin substitute ASP arbitrage are performing exactly as the BTK thesis predicted.

Organogenesis (NASDAQ: ORGO) — Reported May 7 ✓ Net product revenue $36.3M, -58% YoY. Advanced Wound Care $29.5M, -63%. Surgical & Sports Medicine $6.8M, flat. Net loss $53.2M ($0.44/share). Adjusted EBITDA loss $48.2M. Cash $92.1M, no debt.

The revenue number missed even the reduced consensus of $43.3M — the market disruption ran deeper than guided. Gross margin collapsed to 29% from 73% in Q1 2025, a direct reflection of the fixed cost structure hitting a revenue base that fell faster than expenses. The restructuring charge of $2.8M in severance and the $3.3M inventory write-down tied to LCD regulatory changes are the balance sheet fingerprints of a company adapting in real time.

The guidance revision is the headline number. Full-year 2026 revenue guidance was cut to $270–$310M, down from the prior $350–$420M — a 45–52% decline vs. 2025's $564M, versus the prior guidance of 25–38%. Management described the recovery as "more measured" in Q2 than previously assumed, with H1 now expected to decline approximately 49–52% YoY. The second half recovery thesis is intact in the base case but the low end of guidance now assumes the market headwinds extend through H2 at a pace similar to H1.

CEO Gary Gillheeney's framing: the company remains "well positioned to navigate this period of unprecedented disruption" and continues to expect "significant market share gains in the second half of 2026." The ReNu BLA completion is the forward narrative anchor — if approved, it's the only pathway in the company's portfolio that retains ASP+6% reimbursement and it addresses a market well beyond wound care.

Treace Medical Concepts (NASDAQ: TMCI) — Reports May 8 ◷ Consensus: revenue ~$46M, EPS ($0.31). Lapiplasty procedure volume recovery and commercial model scaling are the primary signals. This is a foot-and-ankle read, not a wound care read — but the BTK surgical corridor matters, and Treace's Q1 will be the first 2026 data point on whether the procedural channel is absorbing ASP headwinds through volume. Stock has been under significant pressure at ~$1.90 against a 52-week high of $7.78.

Avita Medical (NASDAQ: RCEL) — Reports May 14 ◷ Consensus: revenue ~$18.3M, EPS ($0.35). Cohealyx interim data released April 14 showed accelerated time to skin grafting — a positive clinical signal ahead of the call. The April 8 BARDA agreement worth up to $25.5M over 10 years is the more significant commercial development. Watch for burn center utilization trends, RECELL commercial momentum, and Cohealyx rollout timeline. Avita's 510(k) and BARDA-backed positioning is structurally differentiated from the CAMP companies absorbing the reimbursement reset.

Sanuwave Health (NASDAQ: SNWV) — Full Q1 Report May 13 ◷ Preliminary revenue $9.6–$9.7M, +3–4% YoY, in line with guidance. Several good-sized deals slipped out of Q1 per management. CEO Morgan Frank called Q1 "a sort of reckoning in the wound care space" — the most candid sector commentary from any executive outside of MiMedx. Full call adds color on the deal pipeline and full-year guidance reaffirmation. Ultramist's positioning as a non-CAMP acoustic pressure wound therapy keeps Sanuwave partially insulated from the skin substitute reset, though the broader market pause is visible in the numbers.

The 2026 BTK Innovation Index scores all public companies in this earnings snapshot — including CMS risk ratings, regulatory pathway classification, and Innovation Scores. Available at belowtheknee.co/innovation-index

The Month in Review

The earnings picture tells the structural story. The market detail fills it in.

The DOJ seizure that landed in April deserves more than a headline. Federal prosecutors seized over $2 million from a Pasadena-based advanced wound care clinic alleged to have submitted $46.6 million in Medicare claims — many for services never rendered. Skin substitute billing went from $252 million in 2019 to over $10 billion in 2024. The fraud enforcement wave is not the cause of the CMS reset; it is the consequence of the same dynamic that made the reset inevitable. These actions will continue, and they will accelerate consolidation by removing the operators most dependent on exploiting the prior environment.

BioLab Holdings announced a strategic partnership with SweetBio to expand its wound care solutions continuum. SweetBio's APIS platform — billed under HCPCS A2010 at the $127.28/cm² flat rate — is positioned at the affordable, evidence-supported end of the CAMP market. The partnership reflects where distribution logic is moving: toward products that work at the new rate, not against it.

WoundScribe AI launched its WoundScribe-on-Wheels platform — the first AI-native documentation and workflow system built specifically for mobile wound care providers. More on the DME and mobile wound care read in The Signal section below.

Tonight's Organogenesis Q1 report — $36.3M revenue, guidance cut to $270–$310M for the full year — is the single most significant data point to drop this week. See the full analysis in the Earnings Snapshot above. The short version: the disruption ran deeper than even management's reduced guidance, gross margin collapsed to 29%, and the recovery timeline has been extended. The ReNu BLA remains the strategic counterweight.

The European Signal

The 36th European Wound Management Association Congress, co-hosted with the German Wound Congress (DEWU), opened this week in Bremen with a clear message from the industry's largest players: the innovation pipeline is real, the clinical evidence is building, and European market development is the next growth frontier.

Smith+Nephew used EWMA as the launch platform for two new products. The ALLEVYN COMPLETE CARE Foam Dressing features a five-layer construction with ExuLOCK Technology designed to lock in exudate and release fewer bacteria into the wound environment. The RENASYS EDGE Negative Pressure Wound Therapy System is designed for portability and simplicity, with an 88% therapy session compliance rate cited in launch materials. Both launches reflect Smith+Nephew's strategy of using European conference platforms to seed products ahead of broader commercial rollout — ALLEVYN COMPLETE CARE was already launched in the US and is now expanding to Europe in Q2. The simultaneous Q1 earnings report (also released May 6) provided the financial context: AWM is growing through diversification, not through the skin substitute channel that is under reset pressure.

Convatec arrived at EWMA with its most data-rich conference presence in recent memory — 13 abstracts accepted for publication and presentation, covering outcomes in hard-to-heal wounds across foam, multimodal, nitric oxide-generating dressings, antimicrobial technology, and Wound Hygiene. The company has launched or received approvals for five new wound care products since 2022: ConvaFoam, ConvaNiox, Aquacel ConvaFiber, ConvaMatrix, and ConvaVAC. It also unveiled Aquacel ConvaFiber in Europe ahead of a broader scale-up. Convatec's EWMA footprint signals a company that has been building its evidence base methodically and is now deploying it commercially across the European market.

Kerecis (Coloplast) took a prominent scientific and educational position at EWMA despite Coloplast's guidance cut this week. Two Kerecis-led symposia — one on value-based wound care implementation and one on intact fish skin in pediatric populations — plus five accepted abstracts across DFU management, war trauma, and comparative healing dynamics reflect the depth of Kerecis's clinical program. Fertram Sigurjonsson, Kerecis founder and EVP at Coloplast, was direct: Kerecis is established in the US market, but European adoption is still early-stage with significant opportunity ahead. The strategic logic of EWMA is clear — European market development is Coloplast's path to compensating for the US reimbursement headwind. The clinical evidence base to support that development is being built in public, one symposium at a time.

The BTK read on EWMA: The conference confirmed what the Q1 earnings reports showed from a different angle. Companies with deep clinical evidence programs — Smith+Nephew, Convatec, Kerecis — are competing on data, channel diversification, and international expansion. The European market operates on a different reimbursement timeline than the US, but the evidence standards that CMS is now enforcing in the US are exactly the standards that position these companies for European market development as well. The same clinical evidence that supports WISeR compliance in the US supports European market access. That alignment is not coincidental — it reflects a broader global convergence in evidence-based wound care standards that the most sophisticated companies recognized years ago.

The Vascular Infrastructure Build Continues

The Stryker/Inari integration is proceeding — creating the only portfolio that combines lower limb orthopedic reconstruction with a category-leading mechanical thrombectomy platform. That combination does not have a direct competitive analog.

Efemoral Medical continues building its long-term dataset for the bioresorbable vascular scaffold. The EVSS technology addresses the fundamental limitation of permanent metallic stents in below-the-knee tibial disease — a segment where long-term patency outcomes remain the dominant unmet need in peripheral vascular intervention.

The SVS Vascular Annual Meeting in Boston (June 10–13) is the next major US data event for the limb salvage and vascular intervention space. Late-breaking abstracts and the PAD/limb salvage sessions will provide the first significant mid-year clinical read across the category.

Procedural Volume Intact, Commercial Pressure Acknowledged

Treace Medical reports tomorrow (May 8). The read matters less for the specific numbers — consensus is already projecting a difficult quarter — and more for what management says about procedure volume trajectory and whether the commercial model scaling they described on the Q4 call is tracking. The stock at $1.90 against a 52-week high of $7.78 reflects a market that has largely priced in near-term difficulty and is waiting for a recovery signal.

Zimmer Biomet's Q1 foot and ankle performance confirmed the orthopedic procedural channel remains structurally intact. The site-of-care shift from HOPD toward physician office and ASC is accelerating — a dynamic that favors companies with flexible procedure economics.

APMA's Annual Scientific Meeting in Nashville (August 6–9) is the next major foot and ankle clinical gathering. As reimbursement policy increasingly intersects with podiatric practice — WISeR documentation requirements, site-of-care migration, ASC coverage pathway expansion — the APMA room carries more commercial relevance than it has in prior cycles.

Three Forward Reads for May and Beyond

1. The RAPID Pathway Changes the Innovation Calculus

CMS and FDA jointly announced the RAPID (Rapid Access Pathway for Innovative Devices) coverage framework this week — a structural change designed to compress the timeline from FDA Breakthrough Device clearance to Medicare coverage from 12+ months to as little as two months. For a market that has spent the first four months of 2026 absorbing what reimbursement takes away, this is the first significant signal about what it might give back — and to whom.

The mechanism matters. Under the prior coverage system, a company could earn FDA Breakthrough Device designation, achieve clearance, and then spend 12 to 18 months in coverage limbo where clinical evidence existed but the reimbursement pathway didn't. That gap has been one of the primary reasons that genuinely differentiated technology has struggled to convert clinical proof into commercial momentum at the pace investors expected.

RAPID doesn't eliminate that gap — but it compresses it materially. For the BTK coverage universe, the companies most positioned to benefit are those already on a Breakthrough Device track with late-stage clinical data: imaging and workflow platforms approaching CPT Category I conversion, Organogenesis with its ReNu BLA submission now complete, and early-stage vascular intervention platforms building toward FDA engagement. The RAPID pathway also has direct read-through for the documentation technology category — platforms that improve clinical evidence generation are now more valuable, not less, as the evidence-to-coverage timeline shortens.

The signal for investors: the evidence bar is rising, but the reimbursement reward for clearing it is getting faster and more accessible. Companies that have been investing in Breakthrough Device designation and rigorous clinical programs are closer to a coverage catalyst than the standard timeline implied six months ago.

2. Mobile Wound Care Is Building Infrastructure — Watch the DME Question

WoundScribe AI's WoundScribe-on-Wheels launch is a subtle signal about where infrastructure investment is going, not just a product announcement. The mobile wound care channel is in a structurally interesting position post-CMS-1832-F. The flat rate eliminates the margin arbitrage that some mobile operators depended on, but it also removes the product-specific billing complexity that created friction in the channel.

The question is whether the site-of-care shift creates durable opportunity in the mobile channel or simply relocates the same competitive dynamics — evidence requirements, documentation burden, prior authorization compliance — to a new setting. That question has a longer answer than this edition can carry.

BTK is developing a full white paper on the DME question — where the next growth arc in this market actually lives, what the site-of-care shift means for operators and investors, and which companies are building the infrastructure to capture it. Stay tuned.

3. The 2027 Differentiated Rate Is the Next Catalyst — And the Policy Stack Is Already Moving

Everything happening in this market right now is positioning for the 2027 Medicare PFS rulemaking cycle. CMS has explicitly stated that the $127.28/cm² flat rate is transitional. Differentiated rates based on FDA regulatory pathway — 361 HCT/P, 510(k), and PMA/BLA — are coming. The proposed rule language will likely surface in the summer 2026 PFS proposed rule. That document will be the most commercially significant single publication in this market in 2026 when it drops.

But the 2027 rate is not the only policy event to track. The full stack — CMS-1832-F already in effect, WISeR prior authorization expanding, and HCT/P reclassification still unresolved — is operating simultaneously. The companies analyzing each policy in isolation are missing the compounding effect. The companies that understand how all three interact are making positioning decisions now rather than reacting after the proposed rule publishes.

BTK published a detailed breakdown of all three policy mechanisms this week — what each does, what it doesn't do, and what the interaction between them means for companies, providers, and investors through 2027.

→ Read: The Three Policy Moves That Will Reshape This Market by 2027

BTK has launched the Signal Interview Series — written Q&A conversations with commercial leaders, investors, clinicians, and operators who are navigating the wound care, limb salvage, and foot and ankle market in real time. These aren't press releases. They're direct conversations with people who have something specific to say about where the market is going and why.

The series is published at belowtheknee.co/interview-series — open access, no login required. If you're building something in this space, working in it, or investing in it, and you have a point of view worth putting on the record, reach out.

May 6–8 | Bremen, Germany 🔥 EWMA-DEWU 2026 — Messe Bremen The 36th European Wound Management Association Congress, co-hosted with the German Wound Congress. 5,000+ international attendees, 150+ exhibitors. In progress this week — see EWMA section above for BTK's read on the conference.

May 14–15 | Austin, TX Advanced Wound Care Summit (AWCS) Business-focused. Explicitly dedicated to the commercial and strategic side of wound care — not a clinical education event.

May 31–June 2 | Indianapolis, IN 🔥 WOCNext 2026 — Indiana Convention Center The WOCN Society's annual conference. The largest wound care nursing event of the year spanning wound, ostomy, continence, and foot/nail care. As documentation standards and site-of-care dynamics elevate the clinical nurse's role in product selection and prior authorization compliance, this room carries more commercial relevance than it has in prior cycles.

June 10–13 | Boston, MA 🔥 SVS Vascular Annual Meeting (VAM26) — Hynes Convention Center The Society for Vascular Surgery's flagship annual meeting. Late-breaking vascular surgery data, PAD and limb salvage sessions, and the largest vascular surgery exhibit hall of the year. The must-attend event for anyone tracking the vascular intervention and limb salvage space.

July 10 | Online WoundCon Summer 2026 HMP Global's virtual wound care conference. Accessible CE for clinicians across all practice settings; a useful mid-year signal for which clinical topics are getting platform time.

August 5–8 | Boston, MA 🔥 Amputation Prevention Symposium (AMP) — The Leading CLTI Meeting The premier global meeting for CLTI and PAD, with BTK/BTA-specific sessions, late-breaking data, and international faculty spanning interventional radiology, cardiology, and vascular surgery. The H2 anchor event for anyone tracking limb salvage.

August 6–9 | Nashville, TN 🔥 APMA Annual Scientific Meeting (The National) — Gaylord Opryland The premier podiatric medicine meeting. Four days of foot and ankle clinical education, research, and networking. The primary gathering for the podiatric physician audience — a core BTK constituency.

September 14–16 | Louisville, KY 🔥 NAWCO HEAL Conference 2026 Advanced practice wound care nursing. Growing in relevance as documentation standards and site-of-care complexity elevate the nurse's role in product selection, prior authorization, and outcomes tracking.

September 23–27 | Kuala Lumpur, Malaysia 🔥 WUWHS 2026 — World Union of Wound Healing Societies The quadrennial global wound healing congress. The Asia-Pacific location reflects where international market growth is pointing.

October 15–18 | Las Vegas, NV 🔥 SAWC Fall 2026 — Caesars Palace Co-located with the NPIAP Fall Conference. The full wound care team under one roof — including a new dedicated Mobile Wound Care Track.

October 22–24 | Anaheim, CA 🔥 DFCon 2026 — JW Marriott Anaheim Resort ALPS's global interdisciplinary diabetic foot conference. Premier first-look venue for next-generation endovascular therapies, AI diagnostics, and regenerative biologics in the diabetic foot and limb preservation space.

December 9–12 | Phoenix, AZ Desert Foot Conference — Sheraton Phoenix Downtown The flagship annual limb salvage and wound care conference for federal service, VA, DOD, and podiatric communities.

If the Q1 2026 earnings picture — and the divergence between the companies navigating this environment successfully and the ones that aren't — raised questions you need answered with more precision, the 2026 BTK Innovation Index is built for exactly that. Every public company in this earnings snapshot is scored across the six dimensions that determine competitive durability in the current environment: technical differentiation, regulatory position, clinical evidence, strategic activity, market presence, and innovation velocity.

Not subscribed yet? → [Click here] If you enjoyed it - forward this to one person in your network who works in this space. belowtheknee.co Independent market intelligence for wound care, limb salvage, and foot & ankle. 

See you next week — Scott